Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04383938 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
A Phase 1 study, sponsored by Aprea Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04383938 is a Phase 1 study that has completed, run by Aprea Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT04383938, a Phase 1 study, has completed, sponsored by Aprea Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies. The study will include a safety lead-in portion followed by a phase 2 expansion portion in specific disease groups.
Interventions
- DRUG APR-246 (eprenetapopt) + Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-06-25 |
| Est. Completion | 2022-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04383938
The ClinicalTrials.gov registry entry for NCT04383938 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aprea Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APR-246 (eprenetapopt) + Pembrolizumab is the first listed.
NCT04383938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04383938 about?
NCT04383938 is a clinical study titled "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies". A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies. The study will include a safety lead-in portion followed by a phase 2 expansion portion in specific disease groups.
What is the current status of trial NCT04383938?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-06-25. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT04383938?
The interventions under investigation include: APR-246 (eprenetapopt) + Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT04383938?
This trial is sponsored by Aprea Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.